dr. liu on cediranib/olaparib in recurrent ovarian cancer
Published 3 years ago • 226 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
1:47
dr. liu on parp inhibitors in recurrent ovarian cancer
-
4:52
cediranib plus olaparib significantly increases pfs in recurrent ovarian cancer
-
2:12
dr. patel on an analysis of olaparib and cediranib for ovarian cancer
-
0:53
dr. annunziata on olaparib and cediranib combination in ovarian cancer
-
4:19
cediranib plus olaparib increases progression-free survival in recurrent ovarian cancer
-
1:23
dr. liu on phase 2 study results of adavosertib in recurrent uterine serous carcinoma
-
2:13
dr. patel on cediranib versus olaparib in recurrent platinum-sensitive ovarian cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
1:25
olaparib in ovarian cancer
-
1:30
dr. mirza on the evolving treatment landscape in recurrent ovarian cancer
-
6:03
olaparib maintenance for recurrent ovarian cancer
-
11:22
olaparib in ovarian cancer
-
1:17
dr. matulonis on the use of immunotherapy in recurrent ovarian cancer
-
5:25
solo-1: frontline olaparib maintenance therapy in ovarian cancer
-
2:35
dr. monk on choosing between parp inhibitors in ovarian cancer
-
1:34
dr. birrer discusses recurrent ovarian cancer treatment
-
2:00
dr. zakashansky on the benefit of maintenance olaparib in brca ovarian cancer
-
1:25
dr. zakashansky on solo2 with maintenance olaparib in relapsed brca1/2 ovarian cancer
-
0:49
dr. matulonis on cps as a potential biomarker in advanced recurrent ovarian cancer